Key Highlights

  • Charles River Laboratories (NYSE:CRL) traded at USD 376.94 on October 28, 2026, up 5.04% on the day, up 20.11% over one week, up 30.37% over one month and up 60.71% over three months, in published market data.
  • Charles River unveiled 2030 targets of 5% to 7% organic revenue growth, a non-GAAP operating margin near 24% and over USD 300 million of cumulative savings, and said 2026 earnings would reach the high end of guidance.
  • UBS upgraded the stock to Buy with a USD 357 target and several other firms raised targets into the low to mid USD 300s, while the shares set a one-year high near USD 359.89 on October 27.
  • The implied price a month ago is about USD 289.10, simple arithmetic on USD 376.94 and the 30.37% gain, and the stock gained 5.04% today and is up 88.35% since the start of 2026.

The Plan Investors Liked

Charles River Laboratories (NYSE:CRL) presented its Pathway to Purpose plan, which targets organic revenue growth of 5% to 7% a year for 2027 to 2030, a non-GAAP operating margin near 24%, low double-digit earnings growth and a cost program, Create the Future, saving more than USD 300 million. It reaffirmed 2026 earnings at the high end of USD 11.15 to USD 11.45 a share and plans to bring its non-human primate supply in house. Published coverage is dated September 24 and October 21, 2026, so the exact investor day date is not fixed here. The company supplies research models, safety testing and laboratory services to drug developers, so its revenue follows biotech funding and pharmaceutical research budgets.

Analyst Support

UBS moved to Buy from Neutral on October 21 with a USD 357 target, and RBC, Bank of America, Deutsche Bank, Jefferies, Morgan Stanley and Baird raised targets, according to published reports. Deutsche Bank had a target of USD 320 and Baird USD 334 from September 25 updates. Results for the quarter ended in June, reported August 5, showed adjusted earnings of USD 3.02 a share against USD 2.77 expected, though revenue of about USD 1.0 billion was down 2.7%. Revenue is therefore not yet growing. Higher targets mean analysts expect the margin plan to work, but ratings can change quickly if orders from biotech clients weaken. Insiders sold about USD 35.2 million of stock over the three months to October 27 under published disclosures.

Risks and What to Watch

Demand from drug developers depends on funding and regulatory policy on animal testing, and revenue was still declining in the latest reported quarter. The 30.37% gain and an 88.35% rise this year leave the shares well above several older targets. Debt and restructuring charges also weigh on reported margins. The third quarter report is on November 4, 2026 before the open, with a call at 9:00 a.m. ET, and the guided margin path is the key test. This is not advice. The stock has also been volatile in the past, and non-human primate availability is a supply risk that the company is trying to manage. Regulatory moves on animal testing could change demand for some of its services in either direction.

Where Things Stand

The answer is that the 2030 targets, a raised 2026 earnings outlook and a wave of analyst upgrades explain the month, even though reported revenue was still falling. Charles River Laboratories (NYSE:CRL) is up 30.37% in a month and 88.35% in 2026. The November 4, 2026 report will show whether growth is returning. Orders and cancellation rates are the metrics to follow, along with margin progress against plan.